Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine.
Oka varicella vaccine induces humoral and cell-mediated immunity to varicella-zoster virus (VZV), even in immunocompromised hosts. This vaccine showed novel adjuvant activity against co-inoculated hepatitis B surface antigen (HBsAg). Either a mixed inoculation of HBsAg with heat-inactivated Oka varicella vaccine at one site or a separate inoculation of HBsAg and live vaccine at different sites induced an antibody response but failed to induce delayed type hypersensitivity (DTH) to HBsAg. In contrast, immunization of HBsAg mixed with live vaccine induced DTH and an enhanced antibody response to HBsAg. The adjuvant activity of Oka varicella vaccine was similar in terms of antibody production to that of alum adjuvant. A T helper cell-dominant immunity to VZV and HBsAg continued for 1 year. Oka varicella vaccine combined with a foreign antigen may serve as a novel polyvalent vaccine for the infectious diseases for which cell-mediated immunity is beneficial.
Phumiamorn
Supaporn
S
Department of Virology, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan.
Sato
Hitoshi
H
Department of Virology, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan.
Kamiyama
Tomoko
T
Department of Virology, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan.
Kurokawa
Masahiko
M
Department of Virology, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan.
Shiraki
Kimiyasu
K
Department of Virology, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan.
D000276:Adjuvants, Immunologic; D000818:Animals; D019433:Chickenpox Vaccine / Q000276:immunology*; D006168:Guinea Pigs; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D007114:Immunization; D018417:Th1 Cells / Q000276:immunology
D000276:Adjuvants, Immunologic; D019433:Chickenpox Vaccine; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines